Jeremy M. Levin - Feb 22, 2024 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
CEO, Director
Signature
/s/ Danielle Mann for Jeremy Levin by POA
Stock symbol
OVID
Transactions as of
Feb 22, 2024
Transactions value $
$0
Form type
4
Date filed
2/26/2024, 05:58 PM
Previous filing
Dec 6, 2023
Next filing
Mar 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +700K $0.00 700K Feb 22, 2024 Common Stock 700K $3.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.